In pancreatic cancer cells and mouse xenografts, EGCG alone and in combination with gemcitabine prevented the “Cadherin Switch” as well as downregulated expression of TCF8/ZEB1, Vimentin, and β-Catenin, thus reducing the mesenchymal phenotype. The gene discussed is ZEB1; the disease is pancreatic neoplasm.